Navigation Links
Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection
Date:1/11/2010

MADISON, N.J., Jan. 11 /PRNewswire-FirstCall/ -- A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company. Quest Diagnostics is the first commercial laboratory in the U.S. to offer a laboratory-developed test based on the Septin9 biomarker.

"Early detection rates are dismally low, largely because many patients find existing tests and procedures invasive or unpleasant," said Jon R. Cohen, M.D. senior vice president and chief medical officer, Quest Diagnostics. "Our ColoVantage(TM) test, which is based on Septin9, has yet to be clinically validated as a screening test. Rather, it may promote further evaluation in patients who have resisted testing in the past or as an adjunct to existing procedures."

Colorectal cancer treated in localized, early stages has a five-year survival rate of 90 percent. Yet, only 40 percent of cases are diagnosed in early stages, due to low screening rates.

Epigenomics has demonstrated in more than a half dozen peer-reviewed studies involving approximately 3,000 specimens of patients with diagnosed colorectal cancer and of healthy control subjects that methylated Septin9 in blood plasma indicates an increased likelihood of colorectal cancer. Epigenomics is sponsoring a multi-center clinical study named PRESEPT in collaboration with Quest Diagnostics and other organizat
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quest Diagnostics Declares Quarterly Cash Dividend
2. HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia
3. MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug"
4. Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
5. SciScout LLC Launches SciAnswers.com, a Science-Based Questions and Answers (Q&A) Site with a Social Networking Perspective.
6. GenomeQuest Places ChIP-Seq Workflow Solution On SDM “Cloud”
7. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
8. GeoVax Labs Requests pre-IND Meeting With FDA
9. Stemedica Requests Pre-IND Meeting With FDA
10. Five Questions About Protopic (tacrolimus) Ointment
11. FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics Focus Diagnostics Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
(Date:5/5/2015)... VetStem Biopharma, proudly announces former ... Schaffer, DVM, as Director of Veterinary Professional Services. ... experience in the veterinary regenerative medicine field Dr ... veterinarian lead organization”. Dr. Alexis Nahama, President ... be responsible for all technical activities in relationship ...
(Date:5/5/2015)... MILFORD, Mass. , May 5, 2015 ... a strategic alliance which offers a first-of-its-kind platform that ... patient access to lab results, transforms the way patients ... Luminate Health provides a HIPAA-compliant ... patients to access, manage, and understand their lab results, ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... 3, 2011  Generex Biotechnology Corporation ( www.generex.com ) (OTCBB: ... to the early diagnosis, and possibly treatment of, Type ... Class II Epitope Hybrids Derived from Proinsulin and GAD ... appears in the April issue of the international peer-reviewed ...
... SAN DIEGO, May 3, 2011 Verenium Corporation (NASDAQ: ... and commercialization of high-performance industrial enzyme solutions, today announced ... 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing. ... the Toronto Convention Center.   James Levine, ...
... VIEW, Calif., May 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: ... first quarter ended March 31, 2011. The net ... $17.6 million compared to a net loss of $14.1 million ... first quarter ended March 31, 2011 was related primarily to ...
Cached Biology Technology:Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 2Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 3Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 4Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing 2Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... This release is available in German . ... channels and ion pumps, and thus specifically control them with ... J. Zlch Prize 2012 to four scientists who initiated and ... optogenetics: Ernst Bamberg of the Max Planck Institute of Biophysics ...
... lot of all the hens in the flock, but the ... sperm - and thus more chicks. This sounds natural, but ... of years, people have tinkered with the development of domestic ... large muscle mass and increased egg-laying, we have at the ...
... autism researchers in the University of North Carolina School of ... latest round of funding from the National Institutes of Health,s ... was ranked No. 2 among the top 25 institutions in ... Autism Coordinating Committee, is one of only two institutions that ...
Cached Biology News:Zülch Prize 2012 for founders of optogenetics 2Zülch Prize 2012 for founders of optogenetics 3Zülch Prize 2012 for founders of optogenetics 4For the rooster, size matters 22 UNC faculty receive Autism Centers of Excellence grants for new research 22 UNC faculty receive Autism Centers of Excellence grants for new research 3
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S ... The gamma secretase is a multiprotein ... and Pen-2; all four proteins are ... gamma secretase complex catalyzes cleavage of ...
... Bio-Beads S-X media are ... for size exclusion chromatography of ... that require organic eluents. The ... toluene, xylene, carbon tetrachloride, dimethylformamide, ...
Biology Products: